This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e115. Learning Objective-Upon completion of this activity, successful learners will be able to diagnose and manage patients with IgG4-sclerosing cholangitis.
I gG4-related sclerosing cholangitis (IgG4-SC), 1 also known as IgG4-associated cholangitis (IAC), 2 is a biliary tract manifestation of IgG4-related diseases (IgG4-RD), which are characterized by systemic, inflammatory, sclerosing lesions with massive infiltrations of IgG4-positive lymphocytes involving many organs including the eye, salivary and lacrimal glands, lungs, pancreas, retroperitoneum, kidneys, and vascular systems. [3] [4] [5] [6] [7] In particular, IgG4-SC is frequently found with pancreatic involvement of IgG4-RD, a condition termed autoimmune pancreatitis (AIP). 8 AIP and IgG4-SC are relatively new clinical entities. In 2001, Hamano et al 9 reported a landmark study, demonstrating significant elevation of serum IgG4 levels in patients with sclerosing cholangitis, and Kamisawa et al 10 proposed these populations as a new clinicopathologic entity, newly coined as AIP, and clinical characteristics and treatment policies have been established. [11] [12] [13] Diagnostic criteria was established in Japan 14 and a nationwide survey revealed that, in Japan, the overall prevalence and incidence rate of AIP were 2.2 and 0.9 per 100,000 individuals, respectively. 15 Meanwhile, biliary involvement of AIP or IgG4-RD was also reported, 16 and regarded as a different clinical entity from primary sclerosing cholangitis (PSC) in terms of responses to corticosteroids, 17 yet the clinical, biochemical, and radiographic features of IgG4-SC have not been well characterized, probably because of the rarity of the disease and lack of globally accepted diagnostic criteria. In 2008, Ghazale et al 18 analyzed the large database of AIP patients at Mayo Clinic, and described the clinical profiles and response to therapy of 53 patients with IAC. Huggett et al 19 demonstrated in 2014 that AIP/IgG4-SC are associated with significant morbidity and mortality in the cohort of 115 patients including 68 patients with IgG4-SC, which represents the largest case series of IgG4-SC reported to date. In 2012, we performed a nationwide survey of PSC and IgG4-SC in Japan, and described the clinical characteristics of 43 patients with IgG4-SC. 20 However, because the main purpose of our 2012 survey was to establish a procedure to differentiate between PSC and IgG4-SC without pancreatic involvement (because these conditions are characterized by similar imaging findings in the biliary tract), only patients without AIP (solitary IgG4-SC) were enrolled; thus, the clinical features of whole IgG4-SC were not fully characterized in our 2012 study.
In 2015, we performed another nationwide survey regarding PSC and IgG4-SC in Japan, which enrolled all patients with IgG4-SC, irrespective of the presence or absence of AIP. In our 2015 survey, we aimed to clarify the demographics, clinical presentation, imaging findings, response to treatment, and outcomes of IgG4-SC in Japan. Herein, we provide a comprehensive description of the clinical features of IgG4-SC, with the largest case series of IgG4-SC patients reported to date.
Patients and Methods

Study Design
This nationwide survey consisted of a questionnairebased, multicenter, retrospective study, designed and conducted in collaboration with the Japanese Biliary Association, the Intractable Hepatobiliary Disease Study Group in Japan, and the Research Committee to establish diagnostic criteria and development of treatment for systemic IgG4-related sclerosing disease in Japan. The study protocol was approved by the Ethical Board Committee of Teikyo University (approval no. 15-001).
A questionnaire regarding demographics, presentation, treatment response, and outcomes of patients with IgG4-SC was sent to 211 referral and tertiary centers covering all areas of Japan (Supplementary Appendix). The practicing gastroenterologists and hepatologists managing patients with IgG4-SC in each center were asked to fill in the questionnaires at the time when the patients visited their facilities.
Diagnosis of Immunoglobulin G4 Sclerosing Cholangitis
IgG4-SC was diagnosed independently by the physicians in each facility, using the clinical diagnostic criteria established by the Japanese Biliary Association in 2012 (Supplementary Table 1) . 21 Definite, probable, or possible diagnosis was established using the criteria. In the analysis presented herein, only patients with definite or probable diagnosis were included. The cholangiographic findings of IgG4-SC were classified according to the work by Nakazawa et al. 22 
Statistical Analyses
Continuous variables are presented as mean AE standard deviation if normally distributed, or median (interquartile range) if not. Survival rate was assessed using the Kaplan-Meier curve and log-rank test. All statistical analyses were performed using SPSS Statistics version 22 (IBM Japan, Tokyo, Japan).
Results
Demographics, Symptoms, and Laboratory Data at Presentation
The responses to questionnaires were obtained from 165 centers out of 211 (response rate, 78.2%). Overall, we enrolled 527 patients with IgG4-SC from 45 centers ( Table 1) . There were no patients with IgG4-SC in 120 centers. The number of definite and probable diagnosis is 489 and 38, respectively. The male/female ratio was 436/91 (83%/17%), indicating male dominance in this disease. The median age was 66.2 years (range, 23.0-88.5 years), and the age distribution indicated that patients in their 60s had the highest risk for developing IgG4-SC ( Figure 1 ). The most frequent symptom at presentation was jaundice (n ¼ 164; 35%), followed by pruritus (n ¼ 63; 13%), abdominal pain (n ¼ 52; 11%), and cholangitis (n ¼ 45; 10%). Of note, it was extremely rare for patients with IgG4-SC to present with symptoms of decompensated cirrhosis, because variceal rupture was noted in only 1 patient, and there were no patients with ascites or encephalopathy. It is also notable that one-quarter of all patients (n ¼ 133; 28%) were diagnosed without any symptom ( Figure 2 ). Among them 126 patients (95%) had other organ involvements of IgG4-RD.
Regarding laboratory data at presentation (Table 1) , the levels of serum alkaline phosphatase were elevated in most patients. However, alkaline phosphatase levels were within the normal range in 108 patients (21%) (Supplementary Figure 1) . Serum IgG4 levels were recorded in 482 out of 527 patients with IgG4-SC, and were above normal range (<135 mg/dL) in 407 patients (84.4%) (Supplementary Figure 2) .
Imaging and Histologic Findings
Cholangiograms were available for all patients with IgG4-SC. According to the classification proposed by Nakazawa et al, 23 intrapancreatic biliary strictures resembling pancreatic cancer (type 1) without any other strictures in the bile ducts represented the most common finding (330 patients; 64%), followed by strictures in the hilar hepatic lesion (type 4; 51 patients; 10%), and both intrapancreatic and hilar lesions (type 3; 49 patients; 10%). Intrahepatic segmental (type 2a) and diffuse (type 2b) strictures in addition to intrapancreatic biliary strictures were detected in 24 and 41 patients (5% and 8%), respectively. Unclassified cholangiographic findings were reported in 20 patients (4%) (Figure 3 ). Histologic examination of the liver and bile duct was performed for 63 and 225 patients, respectively. No histologic specimens were obtained from either the liver or the bile duct for a total of 260 patients.
Other Organ Involvement, Comorbidities in the Biliary Tract, and Malignancies AIP was present in 449 out of 519 patients (87%) assessed for AIP. Other organ involvement included dacryoadenitis/sialadenitis in 72 patients (15%), and involvement of the retroperitoneum (38 patients; 7%), kidneys (6 patients), aorta (6 patients), and lungs (4 patients).
Regarding malignant diseases in the biliary tract, development of cholangiocarcinoma was reported only in 4 cases (0.8%). In these patients, cholangiocarcinoma was diagnosed approximately at the same time as IgG4-SC (in 2 cases), or later (4 months and 4 years, respectively). Malignancies other than cholangiocarcinoma were detected in 21 patients, including lung cancer in 5, gastric cancer in 3, and duodenum cancer in 3. Overall, malignant diseases including cholangiocarcinoma were found in 25 patients with IgG4-SC (4.7%).
Treatment Regimens and Responses
Prednisolone (PSL) treatment following diagnosis was commenced in 458 patients (88%). At the final observation, PSL treatment was terminated or continued in 309 (62%) and 180 (38%) patients, respectively. The PSL doses used for maintenance were 5 mg in 220 patients. Endoscopic dilatation or stenting were performed in 47 (9%) and 252 (50%) patients, respectively. Surgical operations were performed in 41 patients (8%), and malignant diseases were preoperatively suspected in most of the cases referred for surgery.
The treatment responses to these protocols were excellent. Reduction in alkaline phosphatase levels to <50% of pretreatment levels or to within normal range was achieved in 386 patients (87% of documented cases), and alleviation of biliary strictures was noted on the imaging results of 377 patients (90% of documented cases).
Outcomes
The follow-up period was 4.1 AE 3.1 years. At the final observation, PSL treatment was maintained and terminated in 309 and 180 patients, respectively, and therefore maintenance PSL therapy was performed in 63% of patients with IgG4-SC. During observation, 26 patients (5%) were reported to have deceased. No liver transplantation was performed in this cohort. The causes of Values given as median (range), unless otherwise specified. mortality included cholangiocarcinoma, hepatic failure, and infectious disease (eg, pneumonia, sepsis, pseudomembranous enterocolitis) in 2, 2, and 5 patients, respectively. Only 4 patients died because of liver-related or bile duct-related conditions. Cirrhosis progression accounted for 2 deaths. Figures 4 and 5 shows the cumulative mortality for all-cause and liver-related or bile duct disease-related mortality. Overall 5-and 10-year survival rate was 94.5% and 81.0%, respectively (Figure 4) , and the 5-and 10-year survival free from death caused by liver-related or bile duct-related diseases was 98.9% and 97.7%, respectively ( Figure 5 ). During the follow-up period, relapse of IgG4-SC (ie, restenosis of the bile ducts) was noted for 104 patients (19%). The cumulative rate of restenosis was 1.6%, 7.6%, and 16.5% at 1, 3, and 5 years after diagnosis (Supplementary Figure 3) . However, overall survival was similar between patients with and without restenosis (P > .05, log-rank test) (Supplementary Figure 4) .
Discussion
In this study we enrolled 527 patients with IgG4-SC from 45 facilities encompassing all over Japan. This is the largest-ever case series of IgG4-SC, and from the current study we confirmed part of our previous knowledge, and also shed new light on, or even reversed, the concept of IgG4-SC, a relatively new disease.
We found that, at presentation, jaundice, pruritus, and abdominal pain were the main symptoms, but onequarter of patients with IgG4-SC were asymptomatic after investigation of abnormal liver test results. This suggests that, in the course of IgG4-SC, there is a latent phase without apparent symptoms before presentation, in which narrowing of bile ducts is indeed present, yet stenosis resulting in jaundice or abdominal pain does not occur. In Japan, most people older than 60 years have a variety of opportunities for medical check-ups at communities or working places, thereby making earlier diagnosis of IgG4-SC possible. Otherwise, 95% of asymptomatic patients with IgG4-SC had other organ involvements of IgG4-RD and had routine screening before development of IgG4-SC. For diagnosis of IgG4-SC, it is generally agreeable that biomarkers specific to IgG4-SC are absent. The level of serum IgG4, the most characteristic biomarker defining IgG4-SC, is not specific for this purpose. Therefore clinical diagnostic criteria of IgG4-SC were established in Japan and used in this study. In the United States and Europe, by contrast, the HISORt criteria have been frequently used for diagnosis of IgG4-SC (or IAC), 18, 24, 25 and one might argue that IgG4-SC in the Japanese criteria was different from IAC in the HISORt criteria. The HISORt criteria were originally designed for diagnosis of AIP, consisting of histology, imaging, serology, other organ involvement, and response to steroid therapy. 26 In the current study, biopsy specimens from the bile duct were obtained from only 225 out of 511 patients (44%), and this might be an obstacle when applying the HISORt criteria to our cohort. In Japan, the concept of IgG4-SC has been well known to gastroenterologists as a differential diagnosis of biliary tract or pancreatic cancer, and thus pancreatic/biliary tract resection was rarely performed in the patients with IgG4-SC enrolled in this study (only 8%), partly explaining the low rate of histologic confirmation. Indeed, diagnosis of IgG4-SC can be made without histology, simply by applying the Japanese diagnostic criteria (Table 1) . 21 However, most patients (96%) demonstrated cholangiographic findings specific for IgG4-SC (type 1-4). Serum IgG4 levels were elevated in 84% of the patients.
Regarding other organ involvement, AIP and dacryoadenitis/sialadenitis were noted in 87% and 15% of patients, respectively. Responses to steroid treatment were excellent in almost 90% of patients. Therefore, very few, if any, of the individuals enrolled in the current study did not meet the HISORt criteria. Kalaitzakis et al 27 reported that comparable studies from Japan, United States, and United Kingdom showed poor sensitivity of cholangiogram to differentiate cholangiocarcinoma, PSC, and IgG4-SC and one may argue that diagnosis of IgG4-SC mainly based on cholangiogram without histology is doubtful. However, the Japanese criteria used serology, other organ involvement, and responses to steroid as well, and therefore diagnosis with the Japanese criteria is reliable, equal to HISORt criteria.
Unlike PSC, very few patients with IgG4-SC presented with decompensated cirrhosis with ascites, hepatic encephalopathy, or variceal bleeding. Because IgG4-SC is a manifestation of biliary tracts of systemic IgG4-RD causing sclerosing cholangitis, we believed that end stage of untreated IgG4-SC might be biliary cirrhosis and hepatic failure that could be mortal without liver transplantation, similarly to other chronic cholestatic liver diseases, PSC, or primary biliary cholangitis. In the context of this hypothesis, at least part of patients with IgG4-SC who had not had a chance of being appropriately diagnosed at early stages might have proceeded to cirrhosis and be diagnosed with ascites or hepatic encephalopathy. However, this was not the case in our large-scale cohort at all. Moreover, outcomes of subjects in the current study were excellent, with no liver transplantation and only 2 patients who died of hepatic failure. In addition, only 4 cases with cholangiocarcinoma were noted in the whole cohort and 2 patients had been diagnosed during the follow-up period, suggesting that development of cholangiocarcinoma during follow-up is very rare, unlike PSC. Possible reasons for this may include earlier diagnosis at asymptomatic stages, and short follow-up period and retrospective dataset collection in the current study. Furthermore, malignant diseases were found in 4.7% of patients with IgG4-SC during observational period, which was comparable with incidence of cancer in age/gender matched general population in Japan. 28 Taken together, these results suggest that the natural history of IgG4-SC is extremely benign in nature, very rarely progressing to cirrhosis as seen in PSC or primary biliary cholangitis, even if jaundice may occur because of stenosis of bile ducts during clinical course, and being at relatively low risk for developing cholangiocarcinoma. We need to consider, however, another possibility that IgG4-SC might be able to progress to cryptogenic cirrhosis in which any diagnostic clue including elevation of IgG4 or typical cholangiographic findings disappeared.
The current study has several limitations, mainly caused by study design. First, the diagnosis of IgG4-SC was independently performed in each center, and central diagnosis was not done. Although the clinical diagnostic criteria was well known in Japan there might be a bias in diagnosis. Second, patients were not prospectively registered, but enrolled by a retrospective, questionnaires-based manner. Therefore selection or recalling biases might be present. Third, questionnaires were sent to referral and tertiary facilities in Japan where daily clinical practices were extensively performed. Although patients with IgG4-SC are accumulated in these centers, other patients followed by smaller hospitals or clinics, even if not many, were not included. Thus, enrolling only "selected" patients, may overestimate clinical features of IgG4-SC in the real world. Finally, the follow-up period, 4.1 years on average, might be not enough. It is possible that patients with IgG4-SC progressing to cirrhosis or hepatic failure might appear with much longer follow-up period, and this should be done in the future. Also, treatment protocol with PSL was not uniform depending on each facility and therefore outcome might be affected by a variety of protocol, tapering in particular.
Huggett et al 19 demonstrated that AIP and IgG4-SC are associated with significant morbidity and mortality caused by progression to cirrhosis, other organ involvements, and malignancy, in contrast to the findings of current study. The reasons for this difference are explained as follows. First, patients in our cohort were diagnosed in earlier stages, one-quarter of them being asymptomatic. Second, PSL maintenance therapy without termination was continued in 63% of our patients, whereas only 16% of patients received more than 12 months of PSL therapy. Third, this study was a retrospective one and development of malignancy might not be reported in some patients.
In conclusion, we demonstrated the demographics, clinical features, treatment responses, and outcomes of IgG4-SC in this large-scale cohort. Of note, we suggest that the outcome of patients with IgG4-SC is fairly excellent, even though the follow-up period may not be satisfactory. Relapse may occur but overall survival was not affected by the existence of relapse. It is strongly warranted that this cohort will be prospectively followed up in the future and long-term outcomes clarified.
Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at http://dx.doi.org/10.1016/j.cgh.2016.12.038. Supplementary Figure 3 . The cumulative rate of restenosis in patients with IgG4-related sclerosing cholangitis.
Supplementary Figure 4 . The cumulative survival free from death due to liver or bile duct-related diseases, stratified according to the presence of restenosis.
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